Lipid Lowering Drugs in Acute Coronary Syndromes (ACS).

"Declarations Competing InterestsN.A. reports receiving consulting fees and grant support from Novartis. W.K. reports receiving consulting fees and lecture fees from AstraZeneca, Novartis, and Amgen; consulting fees from Pfizer, The Medicines Company, DalCor Pharmaceuticals, Kowa, Corvidia Therapeutics, Esperion, Genentech, OMEICOS, Novo Nordisk, LIB Therapeutics, TenSixteen Bio, New Amsterdam Pharma and Daiichi Sankyo; lecture fees from Berlin-Chemie, Bristol-Myers Squibb, and Sanofi; and grant support and provision of reagents from Singulex, Abbott, Roche Diagnostics, and Dr Beckmann Pharma. W.K. has been a member of the executive steering committees of JUPITER, CANTOS, SPIRE, GLAGOV, COLCOT and ORION. Human and Animal Rights and Informed ConsentThis article does not contain any studies with human or animal subjects performed by any of the authors. Competing Interests N.A. reports receiving consulting fees and grant support from Novartis. W.K. reports receiving consulting fees and lecture fees from AstraZeneca, Novartis, and Amgen; consulting fees from Pfizer, The Medicines Company, DalCor Pharmaceuticals, Kowa, Corvidia Therapeutics, Esperion, Genentech, OMEICOS, Novo Nordisk, LIB Therapeutics, TenSixteen Bio, New Amsterdam Pharma and Daiichi Sankyo; lecture fees from Berlin-Chemie, Bristol-Myers Squibb, and Sanofi; and grant support and provision of reagents from Singulex, Abbott, Roche Diagnostics, and Dr Beckmann Pharma. W.K. has been a member of the executive steering committees of JUPITER, CANTOS, SPIRE, GLAGOV, COLCOT and ORION."

"Funding Open Access funding enabled and organized by Projekt DEAL."